Cantor Fitzgerald Maintains Outperform on Harpoon Therapeutics, Raises Price Target to $24

Cantor Fitzgerald maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and raises the price target from $23 to $24.

Benzinga · 11/13/2019 14:40

Cantor Fitzgerald maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and raises the price target from $23 to $24.